323 related articles for article (PubMed ID: 9740688)
1. Steroid receptor expression in endometria from women treated with tamoxifen.
Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
4. K-ras mutation in tamoxifen-related endometrial polyps.
Hachisuga T; Miyakawa T; Tsujioka H; Horiuchi S; Emoto M; Kawarabayashi T
Cancer; 2003 Nov; 98(9):1890-7. PubMed ID: 14584071
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
[TBL] [Abstract][Full Text] [Related]
6. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Duffy SR; Taylor L
Am J Obstet Gynecol; 2004 Dec; 191(6):1921-7. PubMed ID: 15592273
[TBL] [Abstract][Full Text] [Related]
8. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
[TBL] [Abstract][Full Text] [Related]
11. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
13. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
14. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
al-Alwan NA; al-Kubaisy W; al-Rawaq K
East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
[TBL] [Abstract][Full Text] [Related]
15. [The study on endometrial estrogen receptor and progesterone receptor isoforms in medical abortion women].
Zhu LH; Huang LL; Huang HF
Zhonghua Yi Xue Za Zhi; 2003 May; 83(10):819-22. PubMed ID: 12895330
[TBL] [Abstract][Full Text] [Related]
16. [Morphologic endometrium changes with tamoxifen].
Dallenbach-Hellweg G; Hahn U; Schmidt D
Zentralbl Gynakol; 1996; 118(6):365-9. PubMed ID: 8768015
[TBL] [Abstract][Full Text] [Related]
17. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
18. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
Schulze MH; Buchmann J
Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
[TBL] [Abstract][Full Text] [Related]
19. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and progesterone receptors of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen.
Cohen I; Shapira J; Beyth Y; Bernheim J; Tepper R; Cordoba M; Altaras MM
Gynecol Obstet Invest; 1998; 45(2):126-31. PubMed ID: 9517806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
